InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,230.00
(
-0.15%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,031.49
(
-0.09%
)
Post# of 252300
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Rocky3

Send PM Follow Ignore
Followers 22
Posts 874
Boards Moderated 0
Alias Born 07/31/2010

Rocky3

Re: steveporsche post# 111030

Saturday, 12/18/2010 10:40:26 PM

Saturday, December 18, 2010 10:40:26 PM

Post# of 252300
"The Barclays analysts said Gilenya, recently launched in the United States, had 23 percent of new written prescription starts in November among neurologists, according to data from pharmaceuticals industry research firm ImpactRx."

New scripts at 23%. Wow.

That has to affect Teva and potentially MNTA very strongly, as well as BIIB and others. Or am I missing something?

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up